

## **Supplementary materials**

### **Assessing the health economic outcomes from commercially insured relapsing multiple sclerosis patients who switched from other disease-modifying therapies to teriflunomide, in the United States**

**Lita Araujo<sup>1</sup>, Srikanth Kyatham<sup>2\*</sup>, Kristen G Bzdek<sup>3\*</sup>, Keiko Higuchi<sup>4</sup>, Nupur Greene<sup>5</sup>**

<sup>1</sup>Health Economics & Value Assessment, Neurology and Immunology, Sanofi, 450 Water Street, Cambridge, MA, USA [ORCID: 0000-0002-6863-9340]

<sup>2</sup>*Axtria Inc, Berkeley Heights, NJ, USA (\*at the time of the study)*

<sup>3</sup>Medical affairs, Sanofi, 450 Water Street, Cambridge, MA, USA (*\*at the time of the study*)

<sup>4</sup>Global & US Health Economics & Value Assessment, Neurology and Immunology, Sanofi, 450 Water Street, Cambridge, MA, USA

<sup>5</sup>Health Economics & Value Assessment, Neurology and Immunology, Sanofi, 450 Water Street, Cambridge, MA, USA

**Table S1 Healthcare resource utilization and costs for ambulatory aids and prescriptions (1-year pre- vs 1-year post-index period)**

	1 Year Pre Index	1 Year Post Index	<i>p</i> -Value
Healthcare resource utilization			
All-cause services (event rate/100 person-years)			
Durable medical equipment	0.001	0.001	<0.001
Prescriptions (pharmacy + medical <sup>a</sup> )	0.303	0.342	—
MS-specific (event rate/100 person-years)			
Durable medical equipment	0.001	0.001	0.648
Prescriptions (pharmacy + medical <sup>a</sup> )	0.092	0.113	—
Healthcare costs			
All-cause services, \$PPPY			
Durable medical equipment	69.1	35.8	0.001
Prescriptions (pharmacy + medical <sup>a</sup> )	46,384	62,830	—
MS-specific services, \$PPPY			
Durable medical equipment	68.5	34.7	0.346
Prescriptions (pharmacy + medical <sup>a</sup> )	40,017	53,143	—

**Notes:** The first claim of teriflunomide has been included for 1 year pre index date but not for

1 year post index date. <sup>a</sup>Inpatient and outpatient medical claims. *P*-values calculated using Wilcoxon rank-sum test.


**Abbreviations:** MS, multiple sclerosis; PPPY, per person, per year.

**Table S2 Patient age at MS diagnosis and teriflunomide initiation, and time since MS diagnosis for patients initiated on teriflunomide before and after December 31, 2015**

	Before December 31, 2015	After January 1, 2016
	n=956	n=1060
Age at MS diagnosis, years		
Mean $\pm$ SD	48.2 $\pm$ 9.5	46.6 $\pm$ 8.9
Median (IQR)	49.0 (42.0, 54.0)	47.0 (41.0, 53.0)
Age at initiation, years		
Mean $\pm$ SD	52.2 $\pm$ 9.6	51.6 $\pm$ 9.1
Median (IQR)	53.0 (46.0, 59.0)	52.0 (45.0, 58.0)
Time since MS diagnosis, years		
Mean $\pm$ SD	4.21 $\pm$ 2.4	5.07 $\pm$ 3.1
Median (IQR)	3.96 (2.12, 6.13)	4.71 (2.26, 7.47)

**Abbreviations:** IQR, interquartile range; MS, multiple sclerosis; SD, standard deviation.


**Figure S1 Study design. DMT, disease-modifying therapy.**



\* Last visit = last physical encounter

**Figure S2 DMTs used prior to switching to teriflunomide (1-year pre-index period), (n=1741). (A) Patient using different DMTs prior to switching to teriflunomide. (B) Mean duration of time (days) on different DMT prior to switching to teriflunomide. Error bars show standard deviation. DMT, disease-modifying therapy.**

**(A)**



**(B)**

